AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.

IF 4.6 3区 医学 Q1 ONCOLOGY
Alix E Seif, Sara L McDonough, Emily M Becker-Haimes, Katelyn E Oranges, Danielle Clerico, Jacob Hartman, Kelly Rodock, Lisa A Schwartz, Caitlin W Elgarten, Regina M Myers, Rachael O Puszczynski, Susan R Rheingold, Julie W Stern, Tracey F Jubelirer, Erin A Armideo, Nicholas F Evageliou, R Jennifer Randall, Kathrin M Bernt, Anne F Reilly, Sarah K Tasian, Rosemary K Diamant, Brian T Fisher, Kelly D Getz, Richard Aplenc
{"title":"AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.","authors":"Alix E Seif, Sara L McDonough, Emily M Becker-Haimes, Katelyn E Oranges, Danielle Clerico, Jacob Hartman, Kelly Rodock, Lisa A Schwartz, Caitlin W Elgarten, Regina M Myers, Rachael O Puszczynski, Susan R Rheingold, Julie W Stern, Tracey F Jubelirer, Erin A Armideo, Nicholas F Evageliou, R Jennifer Randall, Kathrin M Bernt, Anne F Reilly, Sarah K Tasian, Rosemary K Diamant, Brian T Fisher, Kelly D Getz, Richard Aplenc","doi":"10.1200/OP-25-00314","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Current care guidelines for children with AML recommend hospitalization during severe neutropenia. However, selected patients discharged before neutrophil recovery have similar chemotherapy course-specific bacteremia and mortality rates to those who remain hospitalized. On the basis of published literature, we developed a toolkit to guide outpatient care after myelosuppressive AML chemotherapy and piloted its implementation at a single institution. We present the pilot clinical and implementation outcomes.</p><p><strong>Methods: </strong>The AML Care at Home toolkit includes a discharge eligibility assessment tool and outpatient management guidelines for pediatric patients with AML and was implemented on November 15, 2022. Toolkit reach, defined as the proportion of postinduction 1 courses with toolkit use (target: 60%), was the coprimary implementation outcome, and total inpatient days per course was the coprimary clinical outcome. Chart abstractions were used to ascertain total inpatient days per course and other clinical outcome designations.</p><p><strong>Results: </strong>During this pilot implementation program, 22 patients underwent 48 postinduction 1 chemotherapy courses. The toolkit was used in 33 (68.8%) courses. Appropriate toolkit use allowed for early discharge in 21 (43.8%) courses and directed inpatient recovery in 11 (22.9%). Median total inpatient days were markedly fewer for toolkit-guided early-discharge courses (8 days, IQR, 5.5-14.5) than toolkit-guided inpatient-only courses (26 days, IQR, 22-39) or when the toolkit was not used as intended (31 days, IQR, 25.3-34.8).</p><p><strong>Conclusion: </strong>Pilot implementation of the AML Care at Home toolkit exceeded our target reach goal and led to fewer inpatient days per course than expected on the basis of previous studies of outpatient neutropenia management. These data reflect the utility of a toolkit created on the basis of published data to identify and support appropriate patients for early hospital discharge and safe outpatient monitoring.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500314"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP-25-00314","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Current care guidelines for children with AML recommend hospitalization during severe neutropenia. However, selected patients discharged before neutrophil recovery have similar chemotherapy course-specific bacteremia and mortality rates to those who remain hospitalized. On the basis of published literature, we developed a toolkit to guide outpatient care after myelosuppressive AML chemotherapy and piloted its implementation at a single institution. We present the pilot clinical and implementation outcomes.

Methods: The AML Care at Home toolkit includes a discharge eligibility assessment tool and outpatient management guidelines for pediatric patients with AML and was implemented on November 15, 2022. Toolkit reach, defined as the proportion of postinduction 1 courses with toolkit use (target: 60%), was the coprimary implementation outcome, and total inpatient days per course was the coprimary clinical outcome. Chart abstractions were used to ascertain total inpatient days per course and other clinical outcome designations.

Results: During this pilot implementation program, 22 patients underwent 48 postinduction 1 chemotherapy courses. The toolkit was used in 33 (68.8%) courses. Appropriate toolkit use allowed for early discharge in 21 (43.8%) courses and directed inpatient recovery in 11 (22.9%). Median total inpatient days were markedly fewer for toolkit-guided early-discharge courses (8 days, IQR, 5.5-14.5) than toolkit-guided inpatient-only courses (26 days, IQR, 22-39) or when the toolkit was not used as intended (31 days, IQR, 25.3-34.8).

Conclusion: Pilot implementation of the AML Care at Home toolkit exceeded our target reach goal and led to fewer inpatient days per course than expected on the basis of previous studies of outpatient neutropenia management. These data reflect the utility of a toolkit created on the basis of published data to identify and support appropriate patients for early hospital discharge and safe outpatient monitoring.

AML家庭护理:一个基于证据的工具包,用于儿科AML化疗后康复的个性化护理设置。
目的:当前AML患儿护理指南建议在严重中性粒细胞减少期间住院治疗。然而,在中性粒细胞恢复前出院的患者与继续住院的患者有相似的化疗病程特异性菌血症和死亡率。在已发表文献的基础上,我们开发了一个工具包来指导骨髓抑制性AML化疗后的门诊护理,并在单个机构试点实施。我们介绍了试点临床和实施结果。方法:AML家庭护理工具包包括儿科AML患者出院资格评估工具和门诊管理指南,并于2022年11月15日实施。工具包覆盖率,定义为入门后课程使用工具包的比例(目标:60%),是主要的实施结果,每个课程的总住院天数是主要的临床结果。使用图表抽象来确定每个疗程的总住院天数和其他临床结果指定。结果:在该试点实施方案中,22例患者接受了48次诱导后化疗。在33门(68.8%)课程中使用了该工具包。适当使用工具包可使21个疗程(43.8%)的患者提前出院,11个疗程(22.9%)的患者直接住院康复。工具包指导的早期出院课程(8天,IQR, 5.5-14.5)的中位总住院天数明显少于工具包指导的单纯住院课程(26天,IQR, 22-39)或未按预期使用工具包的课程(31天,IQR, 25.3-34.8)。结论:AML家庭护理工具包的试点实施超出了我们的目标,并且每个疗程的住院天数比先前门诊中性粒细胞减少管理研究的预期要少。这些数据反映了在公开数据基础上创建的工具包的效用,该工具包可识别和支持适当的患者,以便尽早出院并进行安全的门诊监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.40
自引率
7.50%
发文量
518
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信